Figure 2
An accelerated 6-month CMC timeline proposed for general biologics development. DP, drug product; DS, drug substance; GMP, good manufacturing practice; IND, investigational new drug application; MCB, master cell bank; Tox, toxicology study; UPB, unprocessed bulk; VC, viral clearance.

An accelerated 6-month CMC timeline proposed for general biologics development. DP, drug product; DS, drug substance; GMP, good manufacturing practice; IND, investigational new drug application; MCB, master cell bank; Tox, toxicology study; UPB, unprocessed bulk; VC, viral clearance.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close